{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:21:37Z","timestamp":1791469297490,"version":"4.3.4"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JGO"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> To evaluate the results of an intensive polychemotherapy regimen for Burkitt lymphoma (BL) in sub-Saharan African pediatric centers. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Children with advanced-stage BL (stages II bulky, III, and IV) treated with the GFAOP\u2013Lymphomes Malins B (GFALMB) 2009 protocol in 7 centers between April 2009 and September 2015 were prospectively registered. Treatment regimen contained a prephase with cyclophosphamide followed by 2 induction courses (cyclophosphamide, vincristine, prednisone, high-dose methotrexate [HDMTX]), 2 consolidation courses (cytarabine, HDMTX), and a maintenance phase only for stage IV. HDMTX was given at the dose of 3 g\/m<jats:sup>2<\/jats:sup>. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Four hundred patients were analyzed: 7% had stage II bulky, 76% stage III, and 17% stage IV disease. Median age was 7.3 years, and sex ratio was 1.9:1 (male:female). A total of 221 patients received the whole protocol treatment and 195 achieved complete remission (CR), 11 of them after a second-line treatment. Treatment abandonment rate was 22%. One hundred twenty-five patients died, of whom 49 deaths were related to treatment toxicity. A total of 275 patients are alive, including 25 despite treatment abandonment, but only 110 are known to be in CR with a follow-up &gt; 1 year, indicating a high rate of loss to follow-up. Twelve-month overall survival (OS) was 60% (95% CI, 54% to 66%) and 63%, 60%, and 31%, respectively, for stage II bulky, III, and IV. Patients with stage III disease who started second induction course within 34 days had OS of 76%, versus 57% ( P = .0062) beyond 34 days. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The GFA-LMB2009 protocol improved patients\u2019 survival. Early dose intensity of treatment is a strong prognostic factor. Improving supportive care and decreasing loss to follow-up are crucial. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jgo.19.00172","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T20:59:17Z","timestamp":1575406757000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":16,"title":["Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d\u2019Oncologie P\u00e9diatrique"],"prefix":"10.1200","author":[{"given":"Gabrielle C.","family":"Bouda","sequence":"first","affiliation":[{"name":"CHU Yalgado Ou\u00e9draogo, Ouagadougou, Burkina Faso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fousseyni","family":"Traor\u00e9","sequence":"additional","affiliation":[{"name":"CHU Gabriel Tour\u00e9, Bamako, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Couitchere","sequence":"additional","affiliation":[{"name":"CHU de Treichville, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Raquin","sequence":"additional","affiliation":[{"name":"Gustave Roussy Hospital and GFAOP Database Center, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koffi M.","family":"Guedenon","sequence":"additional","affiliation":[{"name":"CHU Sylvanus Olympio, Lom\u00e9, Togo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angele","family":"Pondy","sequence":"additional","affiliation":[{"name":"Centre M\u00e8re-Enfant, Fondation Chantal Biya, Yaound\u00e9, Cameroun"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Moreira","sequence":"additional","affiliation":[{"name":"H\u00f4pital Aristide Le Dantec, Dakar, S\u00e9n\u00e9gal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mbola","family":"Rakotomahefa","sequence":"additional","affiliation":[{"name":"HJRA, Antananarivo, Madagascar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhamed","family":"Harif","sequence":"additional","affiliation":[{"name":"H\u00f4pital 20 Ao\u00fbt 1953, Casablanca, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[{"name":"Gustave Roussy Hospital and GFAOP Database Center, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","unstructured":"Patte C, Brugi\u00e8res L, Terrier-Lacombe MJ: Lymphomes malins non-Hodgkinien de l\u2019enfant, in Kalifa C, Oberlin O, Pein F, et al (eds): Cancer de l\u2019enfant. Paris, France, Flammarion M\u00e9decine-Science, 2008, pp 157-168"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5311.1019"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21452"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22746"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25612"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2011.644881"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09236.x"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1219"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"B13","first-page":"3294","volume":"94","author":"Reiter A","year":"1999","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24975"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01348.x"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S67769"},{"key":"B20","first-page":"332","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Semin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"B23","first-page":"401","volume":"43","author":"Hesseling P","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303103081003"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20254"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26335"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0591-z"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1179\/146532809X402006"},{"key":"B30","unstructured":"Patte C, Gerrard M, Auperin A, et al: Early treatment intensity has a major prognostic impact in the \u201cintermediate risk\u201d childhood and adolescent B-cell lymphoma: Results of the International FAB LMB 96 Trial. Blood (abstract); 102:491, 2003"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(03)90458-1"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.3.304"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2015.1085933"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200002)34:2<143::AID-MPO15>3.0.CO;2-1"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24407"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-844472"},{"key":"B39","first-page":"113","volume":"13","author":"El-Mallawany NK","year":"2015","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Journal of Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JGO.19.00172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:51:11Z","timestamp":1653821471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JGO.19.00172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1200\/JGO.19.00172"],"URL":"https:\/\/doi.org\/10.1200\/jgo.19.00172","relation":{},"ISSN":["2378-9506"],"issn-type":[{"value":"2378-9506","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2019-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}